Granisetron-d6

CAT: 0804-HY-B0071S2Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-B0071S2Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Granisetron-d6 (BRL 43694-d6) is deuterium labeled Granisetron. Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
CAS Number
[1224925-80-7]
Product Name Alternative
BRL 43694-d6
UNSPSC
12352005
Target
5-HT Receptor; Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Neuronal Signaling; Others
Applications
Cancer-programmed cell death
Field of Research
Neurological Disease; Cancer
Smiles
O=C(C1=NN(C([2H])([2H])[2H])C2=CC=CC=C12)N[C@H]3C[C@]4([H])N(C([2H])([2H])[2H])[C@](CCC4)([H])C3
Molecular Formula
C18H18D6N4O
Molecular Weight
318.45
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Sanger GJ, Nelson DR. Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron) . Eur J Pharmacol. 1989 Jan 10;159 (2) :113-24.|[3]Maleki-Dizaji N, Eteraf-Oskouei T, Fakhrjou A, The effects of 5HT3 receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation. Int Immunopharmacol. 2010 Sep;10 (9) :1010-6.|[4]Boccia RV, Gordan LN, Clark G, Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011 Oct;19 (10) :1609-17.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products